136 related articles for article (PubMed ID: 36698073)
1. Developing a Bayesian hierarchical model for a prospective individual patient data meta-analysis with continuous monitoring.
Wu D; Goldfeld KS; Petkova E
BMC Med Res Methodol; 2023 Jan; 23(1):25. PubMed ID: 36698073
[TBL] [Abstract][Full Text] [Related]
2. Adaptive designs in critical care trials: a simulation study.
Li W; Cornelius V; Finfer S; Venkatesh B; Billot L
BMC Med Res Methodol; 2023 Oct; 23(1):236. PubMed ID: 37853343
[TBL] [Abstract][Full Text] [Related]
3. Designing a Bayesian adaptive clinical trial to evaluate novel mechanical ventilation strategies in acute respiratory failure using integrated nested Laplace approximations.
Hosseini R; Chen Z; Goligher E; Fan E; Ferguson ND; Harhay MO; Sahetya S; Urner M; Yarnell CJ; Heath A
Contemp Clin Trials; 2024 Jul; 142():107560. PubMed ID: 38735571
[TBL] [Abstract][Full Text] [Related]
4. A comparison of Bayesian information borrowing methods in basket trials and a novel proposal of modified exchangeability-nonexchangeability method.
Daniells L; Mozgunov P; Bedding A; Jaki T
Stat Med; 2023 Oct; 42(24):4392-4417. PubMed ID: 37614070
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of predictive capability of Bayesian spatio-temporal models for Covid-19 spread.
Lawson AB
BMC Med Res Methodol; 2023 Aug; 23(1):182. PubMed ID: 37568119
[TBL] [Abstract][Full Text] [Related]
6. Alone, together: On the benefits of Bayesian borrowing in a meta-analytic setting.
Harari O; Soltanifar M; Verhoek A; Heeg B
Pharm Stat; 2023; 22(5):903-920. PubMed ID: 37321565
[TBL] [Abstract][Full Text] [Related]
7. Stochastic curtailment tests for phase II trial with time-to-event outcome using the concept of relative time in the case of non-proportional hazards.
Sharma P; Phadnis MA
J Biopharm Stat; 2024 Jul; 34(4):596-611. PubMed ID: 37574976
[TBL] [Abstract][Full Text] [Related]
8. Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials.
Collier W; Haaland B; Inker LA; Heerspink HJL; Greene T
BMC Med Res Methodol; 2024 Feb; 24(1):39. PubMed ID: 38365599
[TBL] [Abstract][Full Text] [Related]
9. Constructing Relative Effect Priors for Research Prioritization and Trial Design: A Meta-epidemiological Analysis.
Glynn D; Nikolaidis G; Jankovic D; Welton NJ
Med Decis Making; 2023 Jul; 43(5):553-563. PubMed ID: 37057388
[TBL] [Abstract][Full Text] [Related]
10. Bayesian Meta-Analysis for Binary Data and Prior Distribution on Models.
Negrín-Hernández MA; Martel-Escobar M; Vázquez-Polo FJ
Int J Environ Res Public Health; 2021 Jan; 18(2):. PubMed ID: 33477861
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Bayesian spatiotemporal infectious disease models for prospective surveillance analysis.
Kim J; Lawson AB; Neelon B; Korte JE; Eberth JM; Chowell G
BMC Med Res Methodol; 2023 Jul; 23(1):171. PubMed ID: 37481553
[TBL] [Abstract][Full Text] [Related]
12. Bayesian methods: a potential path forward for sepsis trials.
Tomlinson G; Al-Khafaji A; Conrad SA; Factora FNF; Foster DM; Galphin C; Gunnerson KJ; Khan S; Kohli-Seth R; McCarthy P; Meena NK; Pearl RG; Rachoin JS; Rains R; Seneff M; Tidswell M; Walker PM; Kellum JA
Crit Care; 2023 Nov; 27(1):432. PubMed ID: 37940985
[TBL] [Abstract][Full Text] [Related]
13. A Bayesian phase II proof-of-concept design for clinical trials with longitudinal endpoints.
Zhang W; Laird G; Chen J; Yuan Y
Stat Med; 2024 Jan; 43(1):173-183. PubMed ID: 37937591
[TBL] [Abstract][Full Text] [Related]
14. Bayesian design of multi-regional clinical trials with time-to-event endpoints.
Bean NW; Ibrahim JG; Psioda MA
Biometrics; 2023 Dec; 79(4):3586-3598. PubMed ID: 36594642
[TBL] [Abstract][Full Text] [Related]
15. A group-sequential randomized trial design utilizing supplemental trial data.
Kotalik A; Vock DM; Hobbs BP; Koopmeiners JS
Stat Med; 2022 Feb; 41(4):698-718. PubMed ID: 34755388
[TBL] [Abstract][Full Text] [Related]
16. A Bayesian multi-arm multi-stage clinical trial design incorporating information about treatment ordering.
Serra A; Mozgunov P; Jaki T
Stat Med; 2023 Jul; 42(16):2841-2854. PubMed ID: 37158302
[TBL] [Abstract][Full Text] [Related]
17. A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints.
Chi X; Yuan Y; Yu Z; Lin R
Biom J; 2024 Mar; 66(2):e2300122. PubMed ID: 38368277
[TBL] [Abstract][Full Text] [Related]
18. A Bayesian approach to pilot-pivotal trials for bioequivalence assessment.
Lv D; Grayling MJ; Zhang X; Zhao Q; Zheng H
BMC Med Res Methodol; 2023 Dec; 23(1):301. PubMed ID: 38114931
[TBL] [Abstract][Full Text] [Related]
19. Assessing the incidence and severity of drug adverse events: a Bayesian hierarchical cumulative logit model.
Duan J; Gajewski BJ; Sen P; Wick JA
J Biopharm Stat; 2024 Mar; 34(2):276-295. PubMed ID: 37016726
[TBL] [Abstract][Full Text] [Related]
20. A Bayesian model for combining standardized mean differences and odds ratios in the same meta-analysis.
Jing Y; Murad MH; Lin L
J Biopharm Stat; 2023 Mar; 33(2):167-190. PubMed ID: 35920674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
